Related Experiment Video

Updated: Jul 11, 2026

Genome-Wide CRISPR Screen for Unveiling Radiosensitive and Radioresistant Genes
08:32

Genome-Wide CRISPR Screen for Unveiling Radiosensitive and Radioresistant Genes

Published on: May 23, 2025

RNA interference--about the reality to be exploited in cancer therapy

R Bakalova1

  • 1Department of Biophysics, Molecular Imaging Center, NIRS, 4-9-1 Anagawa, Inage-ku, Chiba, Japan. bakalova@nirs.go.jp

Methods and Findings in Experimental and Clinical Pharmacology
|October 9, 2007
PubMed

Insights

RNA interference (RNAi) shows promise for cancer gene therapy, but challenges remain. Silencing one cancer gene may activate others, potentially preserving leukemia cell survival.

Area of Science:

  • Molecular Biology
  • Cancer Genetics
  • Gene Therapy

Background:

  • RNA interference (RNAi) offers potential for cancer gene therapy.
  • Significant challenges exist, including siRNA delivery, transient effects, and long-term side effects.
  • The therapeutic application of RNAi in oncology requires further investigation.

Purpose of the Study:

  • To investigate the broader molecular consequences of oncogene silencing via RNAi in cancer.
  • To explore the potential for compensatory gene activation following RNAi treatment.
  • To assess the impact of RNAi on leukemia cell immortalization.

Main Methods:

  • Microarray analysis was employed to study gene expression profiles.
  • RNA interference was used to silence the bcr-abl oncogene in chronic myelogenous leukemia cells.
  • Gene expression changes were analyzed to identify alterations in oncogenes and antiapoptotic factors.

Main Results:

  • Silencing the bcr-abl oncogene induced the overexpression of previously "sleeping" oncogenes.
  • Upregulation of antiapoptotic genes and factors was observed.
  • These changes contributed to the preservation of immortalization in bcr-abl-positive leukemia cells.

Conclusions:

  • RNAi-mediated silencing of one oncogene can lead to the activation of alternative survival pathways.
  • Compensatory gene upregulation may limit the efficacy of RNAi-based cancer therapies.
  • Further research is needed to overcome these challenges for effective gene therapy.

More Related Videos

Live Imaging to Quantify Cellular Radiosensitivity in Patient-Derived Tumor Organoids05:39

Live Imaging to Quantify Cellular Radiosensitivity in Patient-Derived Tumor Organoids

Published on: April 5, 2024

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo09:19

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo

Published on: February 6, 2015

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Nucleotide Excision Repair01:38

Nucleotide Excision Repair

DNA Distortion and Damage
Cells are regularly exposed to mutagens—factors in the environment that can damage DNA and generate mutations. UV radiation is one of the most common mutagens and is estimated to introduce a significant number of changes in DNA. These include bends or kinks in the structure, which can block DNA replication or transcription. If these errors are not fixed, the damage can cause mutations, which in turn can result in cancer or disease depending on which sequences are...
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...